Hospital Pierre Wertheimer

Research site

France 59 Boulevard Pinel, 69500 Bron, France

8 trials recruiting
Parkinson's disease · Partial seizures · Dementia Alzheimer's type
Adults and children

About Specializations

Hospital Pierre Wertheimer in Bron, France specialises in clinical trials of conditions such as Parkinson's disease, Partial seizures, Dementia Alzheimer's type, Generalised tonic-clonic seizure, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

59 Boulevard Pinel69500 BronFrance

Open in maps ↗

Recruiting now: 8 trials
Conditions studied: 20

More sites in Bron France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

23 clinical trials

Parkinson's disease

Recruiting

Study on Amantadine for Reducing Motor Fluctuations in Advanced Parkinson's Disease Patients

Registered drug

Study on Amantadine for Reducing Motor Fluctuations in Advanced Parkinson's Disease Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Amantadine Hydrochloride
Sponsor:Centre Hospitalier Universitaire De Toulouse

Contact Research Centre

Aneurysm ruptured

Recruiting

Study on the Effects of Dornase Alfa for Patients with Subarachnoid Hemorrhage to Improve Independence After 6 Months

Registered drugNo placebo

Study on the Effects of Dornase Alfa for Patients with Subarachnoid Hemorrhage to Improve Independence After 6 Months

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dornase Alfa
Sponsor:Fondation A De Rothschild

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Long-Term Safety Study of ACP-204 for Adults with Alzheimer's Disease Psychosis

InvestigationalNo placebo

Long-Term Safety Study of ACP-204 for Adults with Alzheimer's Disease Psychosis

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:ACP-204 tartrate
Sponsor:Acadia Pharmaceuticals Inc.

Contact Research Centre

Metastases to central nervous system

Recruiting

Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

Registered drug

Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Institut De Cancerologie De L Ouest

Contact Research Centre

Generalised tonic-clonic seizure+1

Recruiting

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Azetukalner
Sponsor:Xenon Pharmaceuticals Inc.

Contact Research Centre

Partial seizures

Recruiting

Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

Investigational

Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

Investigational

France

Participants:18–64 years · 65+ years
Substances:Azetukalner
Sponsor:Xenon Pharmaceuticals Inc.

Contact Research Centre

Generalised tonic-clonic seizure

Recruiting

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Azetukalner
Sponsor:Xenon Pharmaceuticals Inc.

Contact Research Centre

Neuralgia

Recruiting

Study on Capsaicin Patch for Treating Chronic Neuropathic Pain in Children Aged 12-17

Registered drug

Study on Capsaicin Patch for Treating Chronic Neuropathic Pain in Children Aged 12-17

Registered drug

France

Participants:0–17 years
Substances:Capsaicin
Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Contact Research Centre

Parkinson's disease

Not recruiting

Study on the Long-Term Safety of Tavapadon for Patients with Parkinson's Disease

InvestigationalNo placebo

Study on the Long-Term Safety of Tavapadon for Patients with Parkinson's Disease

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tavapadon
Sponsor:Cerevel Therapeutics LLC

Contact Research Centre

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug

France

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Autoimmune demyelinating disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Registered drug

Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug

France

Participants:0–17 years
Substances:Dimenhydrinate
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites